News

COLUMBUS, OHIO April 6, 2021 – Forge Biologics, a cGMP manufacturing and development company, announced today that Timothy J. Miller,...

We are excited to unveil our Hearthside Chat series – our version of a fireside chat - from our home...

The FDA has granted Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation to FBX-101 for treatment of patients...

We're pleased to share that the United Leukodystrophy Foundation has shared our press release, marking yet another avenue of informing...

We are passionate about serving our clients by providing the highest quality vector and leading the industry in technological advancements....

We are thrilled to have a spotlight in National Venture Capital Association's (NVCA) Building Better blog series alongside Molly (McCartin) Bonakdarpour of Drive...

With new beginnings comes new hope. As we enter 2021, screening will begin for the our Phase 1/2 RESKUE trial...

As we begin 2021, we’d like to introduce you to our new Blaze Vector™ AAV production line. Utilizing our proprietary...

Forge Biologics has received IND, IBC, and IRB clearance for FBX-101, a gene therapy for patients with Krabbe disease, a...